Vessel Patency at 24 Hours and Its Relationship With Clinical Outcomes and Infarct Volume in REVASCAT Trial (Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset).

نویسندگان

  • Mònica Millán
  • Sebastià Remollo
  • Helena Quesada
  • Arturo Renú
  • Alejandro Tomasello
  • Priyanka Minhas
  • Natalia Pérez de la Ossa
  • Marta Rubiera
  • Laura Llull
  • Pedro Cardona
  • Fahad Al-Ajlan
  • María Hernández
  • Zarina Assis
  • Andrew M Demchuk
  • Tudor Jovin
  • Antoni Dávalos
چکیده

BACKGROUND AND PURPOSE Higher rates of target vessel patency at 24 hours were noted in the thrombectomy group compared with control group in recent randomized trials. As a prespecified secondary end point, we aimed to assess 24-hour revascularization rates by treatment groups and occlusion site as they related to clinical outcome and 24-hour infarct volume in REVASCAT (Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset). METHODS Independent core laboratory adjudicated vessel status according to modified arterial occlusive lesion classification at 24 hours on computed tomographic/magnetic resonance (94.2%/5.8%) angiography and 24-hour infarct volume on computed tomography were studied (95/103 patients in the thrombectomy group versus 94/103 in the control group, respectively). Complete revascularization was defined as modified arterial occlusive lesion grade 3. Its effect on clinical outcome was analyzed by ordinal logistic regression. RESULTS Complete revascularization was achieved in 70.5% of the solitaire group and in 22.3% of the control group (P<0.001). Significant differences in complete revascularization rates were found for terminus internal carotid artery, M1, and tandem occlusions (all P<0.001) but not for M2 occlusions. In the thrombectomy group, 2 out of 63 patients (3.1%) with modified Thrombolysis in Cerebral Infarction 2b/3 after thrombectomy showed arterial reocclusion (modified arterial occlusive lesion grade 0/1) at 24 hours. Complete revascularization was associated with improved outcome in both thrombectomy (adjusted odds ratio, 4.5; 95% confidence interval, 1.9-10.9) and control groups (adjusted odds ratio, 2.7; 95% confidence interval, 1.0-6.7). Revascularization (modified arterial occlusive lesion grade 2/3) was associated with smaller infarct volumes in either treatment arm. CONCLUSIONS Complete revascularization at 24 hours is a powerful predictor of favorable clinical outcome, whereas revascularization of any type results in reduced infarct volume in both thrombectomy and control groups. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01692379.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Insights From a Concurrent Population-Based Stroke Registry

Recent trials have shown the superiority of endovascular thrombectomy (EVT) over medical therapy alone in certain stroke patients with proximal arterial occlusion. The generalizability of these results is not yet established because these trials included relatively homogeneous populations of patients with moderate to severe strokes caused by proximal occlusions in the anterior circulation. The ...

متن کامل

REVASCAT: A RandomizEd trial of reVascularizAtion with Solitaire FR® device versus best mediCal therapy in the treatment of Acute stroke due to anTerior circulation large vessel occlusion presenting within 8 hours of symptom onset

REVASCAT is a multi-center, randomized, sequential and blinded-endpoint trial. Subjects presenting with acute ischemic stroke within 8 hours from symptom onset and CT angiography (CT) or MR angiography (MRA) proven arterial occlusion of the internal carotid or proximal middle cerebral artery (MCA) (M1) who are either ineligible for intravenous IV alteplase or have received IV alteplase therapy ...

متن کامل

Cost-Effectiveness of Endovascular Stroke Therapy

The currently estimated direct and indirect annual costs of stroke in the United States are $33 billion. Improved therapy is an urgent need not only from a medical perspective but also from an economic point of view. Five randomized controlled trials (RCTs) using latest generation endovascular therapy (EVT) devices (ESCAPE [Endovascular Treatment for Small Core and Proximal Occlusion Ischemic S...

متن کامل

Mechanical Thrombectomy in and Outside the REVASCAT Trial: Insights From a Concurrent Population-Based Stroke Registry.

BACKGROUND AND PURPOSE Recent trials have shown the superiority of endovascular thrombectomy (EVT) over medical therapy alone in certain stroke patients with proximal arterial occlusion. Using data from the Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke due to Anterior Circulation Large Vessel Occlusion Presenting With...

متن کامل

Phone and Video-Based Modalities of Central Blinded Adjudication of Modified Rankin Scores in an Endovascular Stroke Trial.

BACKGROUND AND PURPOSE The standard outcome measure in stroke research is modified Rankin scale (mRS) evaluated by local blinded investigators. We aimed to assess feasibility and reliability of 2 central adjudication methods of mRS in the setting of a randomized endovascular stroke trial. METHODS This is a secondary analysis derived from the Randomized Trial of Revascularization With Solitair...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Stroke

دوره 48 4  شماره 

صفحات  -

تاریخ انتشار 2017